A Sanofi spokeswoman said the company expected feedback from the regulator in the second quarter of 2013. Sanofi shares were 0.3 percent lower at 71.51 euros at 1345 GMT, while Isis was indicated around 7 percent lower in premarket trading in New York. California-based Isis is entitled to 30 percent of total sales of Kynamro once the drug reaches the market, rising to 50 percent for sales over $2 billion. Reporting by Ben Hirschler; Additional reporting by Elena Berton in Paris; Editing by David Cowell